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HPLC fractions of human uremic plasma inhibit the RBC membrane
calcium pump. We have reported that uremic plasma filtrates (UF) inhibit
the red blood cell (RBC) membrane calcium pump. The inhibitor was
dialyzable, smaller than 3,000 molecular weight, heat-stable, and protease-
resistant. In the present study, we used reverse-phase preparative HPLC,
analytical HPLC, and Sephadex G-25 elution to identify inhibitory frac-
tions. Inhibition was confirmed in three different bioassays: (1) Sr2* efflux
in intact RBC, the primary bio-assay; (2) 45Ca efflux in intact RBC; and (3)
calcium ATPase activity in isolated RBC membranes. Active fractions
were analyzed by mass spectrometry, capillary electrophoresis, enzymatic
analysis, gas chromatography-mass spectrometry, and nuclear magnetic
resonance spectroscopy. These demonstrated a number of compounds,
including: sugars, polyols, osmolytes like betaine and myoinositol, amino
acids, and other metabolites, such as 3-D-hydroxybutyrate, dimethylgly-
cine, trimethylamine-N-oxide, guanidinoacetic acid and glycine. Many
individual compounds were then tested for an effect on the calcium pump.
Thus, HPLC was able to separate a substantial number of compounds in
inhibitory fractions. Efforts are under way for precise identification of the
inhibitor, to advance our understanding of uremic toxicity and/or hyper-
tension in CRF.
The pathophysiology of the uremic syndrome remains poorly
defined, and an adequate marker of toxicity is still lacking [1].
Presumably, toxic factors in uremic plasma may affect a central
mechanism in cell biology and thus be responsible for a variety of
systemic symptoms. For instance, Massry and Fadda have pro-
posed that uremia is a "state of cellular calcium toxicity" and have
confirmed high cytosolic calcium levels in a variety of cells [2].
Normally, free cytosolic calcium is maintained at a very low
concentration (near 100 mM) in most cells by the combined
activities of a high affinity—low capacity system (the membrane
calcium pump) and the low affinity—high capacity Na/Ca2
exchanger [3]. Higher calcium concentrations are poorly tolerated
and may cause cell dysfunction or cell death [4]. Impaired calcium
efflux across the cell membrane is one possible mechanism to
increase free calcium levels in uremic cells. In this context, we
have recently shown a circulating inhibitor of the red blood cell
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(RBC) membrane calcium pump in patients with chronic renal
failure [5]. This is in agreement with the observation by Zidek et
al of a small inhibitor of the calcium ATPase in uremic plasma [6].
Since the calcium pump is ubiquitous, these factors could result in
high cytosolic calcium levels in many cells and thus be responsible
for some symptoms of uremic toxicity and/or hypertension.
In our initial study we demonstrated the biological activity
against the calcium pump in both plasma and ultrafiltrate (UF)
samples obtained during hemodialysis [5]. Thus, we characterized
a circulating inhibitor of the RBC calcium pump as a small
molecule (less than 3,000 molecular wt), which was dialyzable and
heat stable [5]. The present study describes the recovery by HPLC
of a uremic plasma subfraction that inhibits the RBC membrane
calcium pump. Further analysis by mass spectrometry (MS),
capillary electrophoresis (CE), enzymatic analysis (EA), gas chro-
matography-mass spectrometry (GC-MS) and nuclear magnetic
resonance spectroscopy (NMR) were done to identify the sub-
stance(s) responsible for the inhibitory effects.
Methods
This study was designed to search for the circulating inhibitor(s)
of the RBC calcium pump in patients with end-stage renal failure
on hemodialysis. We used HPLC analysis of plasma ultrafiltrates
(UF) to separate the substances responsible for the inhihibion.
The primary bio-assay was the inhibition of the RBC calcium
pump, as described below.
Subjects
Ultrafiltrate was collected at the beginning of a hemodialysis
session from the dialysate side of the membrane, in the ultrafil-
tration mode. Plasma UF was pooled from eight patients ranging
in age from 43 to 74 years. Duration of dialysis ranged between
two and nine years, and residual renal function (creatinine
clearance) was 0 to 1 ml!min in all cases. High-flux polysulphone
membranes (N = 5), low-flux polysulfone (N = 1) and he-
mophane (N = 2) membranes were used. Diagnoses included:
chronic interstitial nephritis in three cases, chronic glomerulone-
phritis in three, one IgA nephropathy and one polycystic kidney
disease.
1042
Lindner et al: Calcium pump inhibitors in uremic plasma 1043
1 UF C18 0 F1-F15 F2
1 UF 0 Ion exchange —+ C18 —* SF3-SF1O SF6
2 SF6 0
2 SF6
NH2 0' AP1-AP12 0 AP6-AP12
4, ÷La
AP6, AP1O
NH2 0' AP1-AP12 -0 AP5, AP6, AP8, AP1O, AP11
Sr2 efflux
Sr2 efflux
Ca ATPase
2 SF6 0 NH2 0 AP1-AP12 —0' APi ,AP6, AP7 45Ca efflux
—P043 —s AP5, AP6, AP8, AP11, AP12 Sr2efflux
—s- AP5, AP6, AP9, APi 1 Sr2 efflux
Sffl—Sffl4(AP) -s. AP5/Ssf8, 11—13 Sr2efflux
AP6/Ssf7—8, 11—14
AP8/Ssf6—8, 11—13
3 AP1-AP12 Sephadex G25 Sffl—Sffl4(AP) -. AP6/Ssf 14
AP8/Ssf 11,14
Fig. 1. Summary of the chromatographic separation steps and precedures, fractions obtained, type of bioassay at each stage, and the identity of fractions with
inhibitory effects on calcium transport. Most measurements were made with the Sr2 efflux bioassay. In later stages, findings were confirmed using
measurements of the calcium ATPase in RBC membranes, and of 45Ca efflux in intact RBC. The sequence of confirmatory bioassays shown (Steps 2
and 3) is descriptive, though not strictly chronological. Peaks with/without phosphate are indicated as: +P04, and —P04, respectively. Methods arc
described in the text.
Summary of analytical methods
The chromatographic procedures used to separate the calcium
pump inhibitor in uremic plasma UF were done following a three
step sequence. These procedures are summarized in Figure 1. The
chemical identification of the substances was done in Step 4.
Bioassays were performed after each chromatographic step to test
the calcium pump inhibitory activity of the fractions or identified
substances, A minimum of three experiments were done for each
additional analytical step. Statistical evaluation of differences
between the mean inhibition in each fraction was done by analysis
of variance and by Student's t-test, when appropriate.
Step 1. Semipreparative HPLC. The initial aim was to separate
UF by a semipreparative HPLC to isolate the biological activity.
Calcium pump inhibition was found exclusively in fraction F2 of
15 fractions. Because UF contains electrolytes that may interfere
with the bioassays, it was desalted by ion-exchange and then
further separated on the same HPLC column. Thus, eight sub-
fractions were isolated, named SF3 to SF10.
Step 2. Analytical HPLC. The second aim was to purify the
inhibitory subfraction by an analytical HPLC procedure. Twelve
peaks were separated and isolated from one active subfraction
(SF6), and were named APi to AP12.
Step 3. Desalting and phosphate removal. The last separation
step was a clean-up procedure to remove the phosphate buffer
that was re-introduced during the analytical HPLC. The AP peaks
were desalted by Sephadex G25.
Step 4. Chemical identification of the putative inhibitory sub-
stances. Some substances in F2 were characterized by their
retention time on the semipreparative HPLC. Other methods
were used to identify compounds in the AP peaks, including: mass
spectrometry (MS), capillary electrophoresis (CE), enzymatic
analysis, gas chromatography-mass spectrometry (GC-MS) and
nuclear magnetic resonance spectroscopy (NMR).
Bioassays of Ca2 pump activity
Effects of HPLC fractions on the cell membrane calcium pump
were assessed primarily with one method: the measurement of the
initial rate of Sr2 efflux in Sr2' -loaded intact RBC, where Sr2
can substitute for Ca2 translocation by the Ca2 pump (as Rb
can substitute for the K translocation by the Na-K pump), as
we described for the initial demonstration of a circulating factor in
uremia [5]. In later stages we confirmed the effects of these
fractions with two other methods, namely (1) an assay for the
Ca2/Mg24 -ATPase activity (the enzymatic counterpart of cal-
cium transport by the calcium pump [7], and (2) a direct mea-
surement of calcium efflux using 45Ca2 in intact RBC. These
methods are described below.
Sr efflux in intact RBC
Preparation of RBC. Briefly, venous blood from healthy normo-
tensive controls was collected in heparinized tubes, and was
centrifuged at 1,750 x g for 10 minutes at 4°C to separate the
plasma and the buffy coat. The RBC pellet was immediately
washed twice at 4°C with isotonic NaCI and re-suspended to a
hematocrit of 10% in a Na-K loading medium containing (in
mmol/liter): 75 NaCI, 75 KCI, 10 MOPS-Tris buffer (pH 7.4 at
Step Material Separation procedure Fractions/peaks Inhibition Bioassay
Sr2 efflux
Sr2 efflux
3 AP1-AP12 0 SephadexG25 0'
5,
3 AP1-AP12 0 SephadexG25 0
Ca ATPase and
45Ca efflux
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37°C), 10 glucose and 0.1 MgC12. The washed RBCs were loaded
with SrC12 (2 mmol/liter) using the calcium ionophore A 23187
(final concentration 6 p.mol/liter), added to the loading media.
RBC were incubated for 20 minutes at 37°C with continuous
mixing. The ionophore was removed by centrifugation for five
minutes at 4°C and by re-suspension in loading media with added
bovine serum albumin at a final concentration of 1 g/liter, and
SrCI2 (2 mmol/liter). Cells were incubated twice at 4°C for 10
minutes, washed, and the second time SrC12 was omitted. To
reconstitute their normal ATP Content the RBC were washed and
incubated twice for 10 minutes at room temperature in loading
media containing (mmol/liter): 5 inosine, 2 adenine, 5 Na2HPO4,
and 10 MOPS-Tris buffer (pH 7.4 at 37°C), 10 glucose and 0.1
MgCI2. Finally, cells were washed three times in cold loading
media, containing I mmol/liter MgC12.
Measurement of Sr2 efflux. The initial rate of Sr2 effiux was
measured for 20 minutes at 37°C in the control state, and during
exposure to different UF fractions. In control experiments we
confirmed linearity of Sr2 efflux during this period. Previous
experience had shown that addition of 20% uremic plasma or UF
to efflux medium induced a clear-cut inhibitory effect on the initial
rate of Sr2 efflux from intact RBC [51. For this step, Sr2-loaded
cells (approximately 2 ml) were re-suspended in 5 ml of Na-K
efflux medium containing (in mmol/liter) 20 NaCl, 130 KC1, 10
MOPS-Tris buffer (pH 7.4 at 37°C), 1 MgC12, and 10 glucose. This
medium was previously shown to prevent a "Gardos effect" and to
maintain a stable cell volume and hemoglobin concentration
during the efflux step [5]. Two hundred and fifty microliters of the
cell suspension were added to 1 ml of the efflux media, for
duplicate measurements of Sr2 effiux. After incubation the tubes
were rapidly chilled at 4°C for two minutes, centrifuged at 1750 g
for five minutes at 4°C, and the supernatants were transferred into
tubes for Sr2 analysis by atomic absorption spectrophotometry
(AA). A portion of the cell suspension was used for measure-
ments of hematocrit, and for intracellular Sr24 concentration by
AA (Perkin-Elmer 5000 spectrophotometer). All AA measure-
ments were done in duplicate. Coefficient of variation was less
than 5% within-runs and less than 10% between-runs.
45Ca2 Efflux in intact RBC
The method is essentially the same as described for Sr2 ,with
the following differences. First, we measured actual calcium
transport by replacing 45Ca2 for Sr2. Scintillation counting was
used instead of AA, thus avoiding a potential matrix artifact that
might quench the Sr2 signal in the AA, such as phosphate or
other substances present in the sample. Washed RBC were
re-suspended to a hematocrit of 10% in the Na-K loading
medium and Sr2 was omitted. Instead, 1 mmol!liter CaCI2 was
added pIus 1 p.Ci 45Ca24. Specific activity was 5.27 X 1011
cpm/mole. The calcium ionophore A 23187 was added at 4 p.M
final concentration. Subsequent steps were the same as for the
original method with Sr2. For measurements of calcium effiux by
the calcium pump, 125 p.1 of the cell suspension were added to 0.5
ml of the effiux media, for duplicate measurements of 45Ca2
effiux during incubation for 10 minutes at 37°C. After incubation
the tubes were rapidly chilled and centrifuged, and the superna-
tants were transferred into vials for 45Ca2 analysis by scintillation
counting. The initial intracellular calcium content was 2.5 to 3.0
m, as measured in RBC hemolyzed with 20% perchloracetic
acid.
Control experiments (not shown) demonstrated that, as with
Sr2, Ca2 effiux was linear for 20 minutes at 37°C, it decreased
to near zero at 4°C, and was suppressed more than 90% by 1 msi
vanadate or lanthanum, known inhibitors of the RBC calcium
pump that have no apparent physiological function. Coefficient of
variation was less than 5% both for within-runs and between-runs.
Ca2 /Mg2 - ATPase activity in isolated RBC membranes
This method was used as previously described by our laboratory
[81. Briefly, multiple membrane-bound ATPases [Mg2, Na17K,
basal Ca2, and calmodulin (CaM)1-activated Ca2 ATPases are
measured simultaneously in 96-well microtiter plates.
Membrane preparation
RBC membranes are prepared from outdated human cells, as
described [81. RBC are washed repeatedly in ice-cold 154 mM
NaC1 (saline) and then hemolyzed by the addition of imidazole
buffer (20 mrvi, pH 7.4), containing EGTA (0.5 mM). Membranes
are then washed x3 in imidazole buffer without EGTA and
separated by centrifugation at 33,000 g for 10 minutes. Mem-
branes are re-suspended in histidine-imidazole buffer (40:40 m,
pH 7.1) and used for the ATPase assay. Membrane protein was
determined by the BCA method [9].
ATPase assay
The ATPase incubation media contained combinations of
several of the following components in a final volume of 100 p.!,
(in mM): standard assay buffer, histidine 18, imidazole 18, MgCI2
3, NaCl 80, KC1 15, EGTA 0.1 (with or without CaCl2 0.2, at pH
7.1), membrane suspension (0.0075 mg protein), ouabain 0.1, and
CaM 30 n. Reagents, membranes and test HPLC fraction were
added to the wells, and the reaction was started with the rapid
addition of 3.0 mri ATP (pH 7.1). The enzymatic activity was
stopped by addition of 25 p.1 SDS solution (5%, wt/vol). This
eliminated the need for centrifugation to remove precipitated
protein. Finally, release of inorganic phosphate (P1) was measured
by a modification of the Fiske and Subarow method [10], with
ascorbate as the reducing reagent. This rapid, non-isotopic
method is very reproducible, and has a coefficient of variation of
less than 6%, for within-run and for between-run observations [81.
All measurements were done in triplicate.
Chromatographic separation
Step 1. Semipreparative HPLC. Ultrafiltrate was first filtered
through a 0.2 p. filter (Minisart NML Sartorius GmbH, GOttingen
Germany; Fig. 1). UF was separated by semipreparative reversed-
phase HPLC using a 10 p. RSil C18 column (250 x 10 mm;
Bio-Rad Laboratories S.A.-N.V., Nazareth Eke, Belgium), at a
flow rate of 3 mI/mm, with a linear gradient of 50 mmol/liter
formic acid, pH 4.00, from 100% to 0%, and methanol 0% to
100% over 60 minutes. These procedures resulted in a separation
based on polarity (hydrophilic substances appearing in the first
eluates, and lipophilic compounds at the end). Peaks were de-
tected by monitoring of UV-absorption at 254 nm. Fifteen
fractions (Fl to F15) were collected and lyophilized. Fraction 2
(F2), with an elution time from four to eight minutes, had the
most pronounced inhibitory effect on the calcium pump in the
RBC. Electrolyte concentrations in re-suspended F2 were similar
to those of the original plasma UF. To exclude a nonspecific effect
of electrolytes on the calcium pump or a "matrix" artifact on AA
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measurements of Sr2, total UF was desalted by passage through
a 5 ml deionizing column (AG-501-X 8 mixed-bed, anion-cation
resin; Bio-Rad) before fractionation by HPLC. To narrow the
search for the substances responsible for the inhibition, desalted
UF was chromatographed using the same reversed-phase C18
column, using ammonium formate/methanol as eluents but with a
shorter gradient profile. Samples were collected at one minute
intervals resulting in eight new subfractions: SF3 to SF10. Sub-
fraction 6 (SF6) contained the most pronounced inhibitory activity
on the calcium pump.
Step 2. Analytical HPLC of SF6, SF6 was lyophilized, concen-
trated 50 times, and dissolved in water/acetonitrile (70/30 vol/vol).
This solution was separated by analytical HPLC on an aminopro-
pyl column (250 >< 46 mm), (Bio-Sil NH2 90-5 S; Bio-Rad). The
flow rate was 1 ml/min. A number of elution buffers were tested,
including phosphate/NaOH, NaC1, and ammonium/formate. UV
absorption was monitored at 195 and 254 nm. A gradient of buffer
and acetonitrile 90% to 0% at 35 minutes was programmed. We
found that phosphate buffer 5 mmol/liter at pH 7,47 gave the most
reproducible separations. Twelve peaks were separated: APi to
AP12. They were lyophilized and submitted to the Sr2 efflux
bioassay. The AP peaks 6 to 12 contained the highest inhibitory
effect.
Step 3. Removal of phosphate from AP peaks by Sephadex G25.
During analytical HPLC phosphate was re-introduced as a buffer
in concentrations approaching that of normal or uremic plasma.
Therefore, AP peaks were desalted using a 10 ml Sephadex G25
column (HiTrap Desalting 5 ml; Pharmacia Biotech AB, Upp-
sala, Sweden), eluted with 0.25 mol/liter ammonium acetate in a
PO43-containing and a non-P043-containing fraction. Both
were lyophilized and submitted to the Sr2-efflux bioassay.
Next, the AP peaks were eluted over a Sephadex G25 column
and separated in narrower fractions called Ssf 1 through Ssfl4.
Ssfl to Ssf4 corresponded with the void volume of the Sephadex
column and were discarded. All other fractions, SsfS through
Ssfl4, were tested on more than one type of bioassay to confirm
the presence of an inhibitory effect.
Step 4. Identification of specific substances. Identification of
substances was first based on the elution on the semipreparative
C18 column after spiking with compounds known to be retained in
uremia. Substances which eluted in F2 were tested for an inhibi-
tory effect with the main bioassay. Enzymatic analysis of urea and
glucose were performed on the AP peaks. MS, NMR, GC-MS and
CE were applied to identify compounds in the AP-peaks. NMR
analysis was performed on the Sephadex fractions (Ssf) of the
AP-peaks.
Results
Step 1. Initial findings with semipreparative HPLC
The chromatographic separation sequence, name of fractions
and biologic activity are summarized in Figure 1. Uremic UF was
separated into 15 fractions by semipreparative HPLC, as de-
scribed above. A typical chromatogram (Fig. 2) describes the
elution profile by UV monitoring at 254 nm. The bulk of the mass
elutes to the left of the chromatogram, primarily represented by
low molecular weight, hydrophilic compounds.
Each HPLC fraction was dissolved in Sr2 efflux medium at a
20% final vol/vol ratio, and then incubated with Sr2-loaded RBC
to evaluate their impact on the calcium pump activity. A summary
0 60
Time, minutes
Fig. 2. UF was separated into 15 fractions by semipreparative, reversed
phase HPLC using a JO RSiI C18 column, at a flow rate of 3 ml/min, with
a linear gradient of 50 mmol/liter formic acidpH 4.00 from 100% to 0%, and
methanol 0% to 100% over 60 minutes. UV absorbance was monitored at
254 nm. This typical elution profile shows that the bulk of mass elutes on
the left of the chromatogram, and primarily represents low molecular
weight, hydrophilic compounds. Several peaks appear in Fraction 2 (F2),
which contains most of the calcium pump inhibitory activity.
Ni Fl F2 F3 F4 F5 F6 F7 F8 F9F1OF11F12F13F14F15
Fraction
Fig. 3. A summary of seven experiments in which all 15 HPLC fractions
were evaluated for a possible effect on calcium pump activity. Values indicate
group mean SEM. Fraction F2 induced a strong inhibitory effect on the
calcium pump, compared to cells in the presence of the control buffer. All
other fractions were less active and results were not different from those
in normal plasma (NI), that was tested as a comparison.
of seven experiments is shown in Figure 3. Fraction F2 induced a
strong inhibitory effect on the calcium pump, compared to cells in
the presence of the control buffer. All other fractions were less
active and results were not different from those in normal plasma
(NI), that was tested as a comparison. F2 effects exhibited a linear
dose-response, at concentrations ranging from 0 to 100% dose, as
shown in Figure 4.
To evaluate the possibility of a non-specific effect of phosphate
on either the RBC membrane Sr2 transport or a "matrix" effect
during Sr2 measurements by AA, UF was desalted in an
exchange column, lyophilized, and re-suspended in buffer for
repeated testing with the bioassay. Residual electrolyte concen-
trations in deionized materials were (in mmol/liter): PO43 0.1,
Na 12 and K 0,8. These samples were further diluted to a final
concentration of 20% (vol/vol) in RBC buffer, as normally used in
the Sr2 bioassay. Although some inhibitory activity is lost during
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Fig. 4. Typical dose-response relationship of calcium pump inhibition by
fraction F2. Effects exhibited a linear dose-response, at concentrations
ranging from 0 to 100% dose. It should be noted that 100% of F2
corresponds to the full dose used in all experiments (that is, 20% vol of F2
in control buffer). The linear dose-response is based on one experiment
done in duplicate. The activity of the sample used in this case was on the
low range for the group of seven cases shown in Figure 3 (mean SEM).
y 1.6420 + 0.199696x; r2 0.946.
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Fig. 5. UF was desalted by mixed bed ion-exchange chromatography, to
exclude a nonspecific inhi bit oty effect of electrolytes that usually elute with F2.
Although some inhibitory activity is lost during desalting, fractions can
then be concentrated into smaller volumes. Desalted F2 again demon-
strates a linear dose-response, with a maximum of 60% inhibition at (x5)
the normal concentration of fraction/RBC buffer. Thus, calcium pump
inhibition is not due to salts contained in the uremic filtrate. y = 1.6420 +
0.19696x, r2 = 0.946.
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—20 0 20 40 60 80 100 120 Fig. 6. The desalted UF was re-chromatographed by HPLC (formate buffer!
methanol) on a C18 RP column, and further separated into 8 subfractions,
% Dose SF3 through SF10. The effects of SF3 to SF10 on the calcium pump were
compared to a mix of all subfractions and to normal plasma. The strongest
inhibitory activity was found in SF6, and then in SF5, which were more
active than a mix of all the suhfractions (All), and almost twice as
inhibitory than normal plasma (NI), used for comparison.
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bioassay of SF3 to SF10 were compared to a mix of all sub-
fractions and to normal plasma. As shown in Figure 6, the
strongest inhibitory activity was found in SF6, and then in SF5,
which were more active than a mix of all the subfractions, and
almost twice as inhibitory than normal plasma, used for compar-
ison.
Step 2. Purification of SF6 by analytical HPLC
For further purification, the most active SF6 was separated into
12 peaks (named APi through AP12), on an aminopropyl column
with a phosphate buffer/acetonitrile gradient. A typical elution
profile is shown in Figure 7. Peaks AP6 through AP12 appeared to
strongly inhibit the calcium pump. Acetonitrile per se (30, 70, and
100%, vol/vol) had no inhibitory effect on the bioassay (data not
shown). On the other hand, in peaks AP6 through AP12 we
measured high phosphate concentrations in parallel to the appar-
ent calcium pump inhibition (Table 1). Therefore, phosphate
re-introduced as a buffer of the separation sequence may induce
an artifact in the Sr2 bioassay. To reduce the "matrix" effects of
phosphate on the AA measurements we added lanthanum 1% to
the samples. We found that in the presence of lanthanum the
apparent inhibition was canceled in many fractions (AP7 to AP9),
while others (AP6) remained fully active (from 16 to 18% activity
with lanthanum), or just decreased to a lower level (AP1O, that
went from 83 to 26% inhibition). These findings suggest that
reintroduction of phosphate with the eluent can interfere with
accurate Sr2 readings by AA and samples may appear to be
inhibitory. More importantly, cancellation of the quenching effect
of phosphate by lanthanun unmasked a real inhibitory effect of
other substances present in the same fraction.
Step 3. Desalting and phosphate removal from AP peaks by
Sephadex G-25
Phosphate buffer gave the best resolution for the chromato-
graphic analysis. Therefore, to avoid the quenching effect on the
Sr2 bioassay, phosphate was removed from the AP peaks by
the ion-exchange step, there was a linear dose-response to de-
salted UF, as shown in Figure 5. Therefore, the calcium pump
inhibition is not due to phosphate or other electrolytes in the
uremic UF.
The desalted UF was rechromatographed by HPLC (formate
buffer/methanol) on a C18 RP column, and further separated into
8 subfractions, SF3 through SF10. Effects on the Sr2-efflux
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Fig. 7. For further punfi cation, the most active SF6 was separated into 12
peaks (named APi through APJ2), on an aminopropyl column with a
phosphate buffer/acetonitrile gradient 5 mmol/liter atpH 7.47, which resulted
in the most reproducible separations. A typical elution profile is shown.
Peaks were separated and tested on the Sr2 efflux bioassay. The AP peaks
6 to 12 contained the highest inhibitory effect. Acetonitrile per se (30, 70,
and 100%, vol/vol), had no inhibitory effect on the bioassay.
Peak
% Inhibition/CT
%
[P041
mmol/liter
APi 1 0.18
AP2 —3 0.22
AP3 3 0.23
AP4 7 0.27
AP5 10 0.22
AP6 16 1.28
AP7 32 2.39
AP8 20 1.76
AP9 23 2.15
AP1O 93 5.59
API1 90 16.8
API2 93 11.2
P04 buffer (low) 34 2.74
P04 buffer (high) 84 7.03
elution over a Sephadex G-25 column, to obtain phosphate-
containing and phosphate-free fractions. Both types of fractions
were tested in parallel on the same Sr2-loaded RBC. A summary
of two such studies is shown in Figure 8. The phosphate-free
Sephadex fractions of AP peaks 5, 6, 8, 11 and 12 are strongly
inhibitory, and in some cases more inhibitory of the calcium pump
than phosphate-containing fractions.
To narrow the inhibitory zone in the AP peaks, 14 fractions
were collected during the elution over the Sephadex G25 column
as described above. A number of phosphate-free Sephadex sub-
fractions (Ssf) of AP peaks inhibited Sr2-efflux more than 20%
compared to controls. This was the case for Ssf8 and Ssfl 1 to 13
from peak AP5, for Ssf7; Ssf8, and Ssfll to 14 from peak AP6, and
for Ssf6 to 8, and SsF11 to 13 from peak AP8. Therefore,
AP Peak
Fig. 8. Phosphate was reintroduced during the analytical HPLC separation
step. Therefore, to avoid the quenching effect on the Sr2* bioassay,
phosphate was removed from the AP peaks by elution over a Sephadex
G-25 column, to obtain (A) phosphate-free and (B) phosphate-containing
fractions. Both types of fractions were tested in parallel on the same
Sr2-loaded RBC. A summary of two such studies is shown in the Figure.
The phosphate-free Sephadex fractions of AP peaks 5, 6, 8, 11 and 12 are
strongly inhibitory, and in some cases more inhibitory of the calcium pump
than phosphate-containing fractions.
Sephadex separation and phosphate removal unmasked a true
inhibitory effect of other substances present in these fractions.
Confirmation of inhibitory activity by other methods
To confirm the presence of an inhibitor of the calcium pump,
and to rule out an artifact of the assay system, we tested the effect
of P04-free AP Sephadex peaks on the calcium ATPase activity in
isolated RBC membranes. Because only small amounts of mate-
rials were available, these peaks were diluted four times, and
tested at a smaller dose, 10% volume (usually 20% for Sr2
efflux). In spite of the dilution and smaller dose used, Figure 9
shows a strong inhibitory effect of peaks AP5 and AP8, and clear
effects of AP6, AP1O and AP1I on calcium ATPase activity in its
calmodulin-activated (CaM) state. On the other hand, these
subfractions had little effect on the calcium ATPase in its basal
state, or other ion ATPases (not shown).
Further evidence of an inhibitor is the finding that individual
subfractions that inhibited either Sr2 efflux or the calcium
ATPase activity in RBC membranes, had the same effect on
45Ca2 efflux in intact RBC (the most specific measurement of
transport by the calcium pump). Table 2 data confirm that a
2
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which showed activity in more than one bio-assay, were submitted
for further analysis by GC-MS, CE and NMR. Several groups of
substances were present, such as amino acids, organic acids,
sugars and polyols. GC-MS demonstrated the presence of sugars
and polyols. Glucose, mannose, and talose were found in AP7 and
in lower quantity in AP8 and AP9. Altrose and glucitol (sorbitol)
were also found in AP7 and AP8. Myo-inositol was demonstrated
mostly in AP9 and in AP8 and galactose in AP9. The occurrence
of organic acids was shown with CE: lactic acid was found mostly
in AP8 and less in AP7; acetic acid and glycolic acid mostly in AP9
and less in AP8. NMR analysis confirmed the preceding findings.
In addition, we found several amino acids, such as: valine in AP6,
alanine in AP6 and AP8, glutamate/glutamine mostly in AP8 and
5 6 7 8 9 10 11 12 less in AP7, glycine in AP9. Propionic acid, initially found in SF6,
AP k was also detected in AP9.ea Sephadex subfractions (Ssf) were analyzed by NMR. Each
subfraction of a peak contains qualitatively the same metabolites,
but quantitatively they vary. The most predominant metabolites
were alanine, lactate, myo-inositol, and glutamine/glutamate, con-
firming the previous analysis. Finally, NMR was useful to identify
additional metabolites: 3-D-hydroxybutyrate, dimethylglycine, tn-
methylamine-N-oxide, betaine, guanidinoacetic acid and glycine.
Initially, we submitted the following substances to the Sr2
bio-assay method: urea, creatinine, arginine, proline, and propi-
onic acid. All were tested twice in concentrations up to 10 times
normal (Table 4). More recently, a larger group of substances
were tested using the RBC calcium ATPase assay, and occasion-
ally the 45Ca effiux method. None of these had significant inhib-
itory activity on the calcium pump. All compounds tested and
their concentrations are listed on Table 4.
A number of reports [11, 12] have suggested that parathyroid
hormone (PTH) may be responsible for the increased cytosolic
calcium content in uremia. Therefore, we also tested the effects of
PTH (1-34 amino-terminal fragment, at i0, 108, and i0— M)
in two different preparations: (1) dissolved in 10 mrvi acetic acid, or
(2) in 0.1% BSA, using the Sr2 bio-assay. In addition, we tested
intact human PTH (at 10_8, and i07 M, in 10 m acetic acid)
using the ATPase assay. Neither preparation of PTH nor the
vehicles used had an effect on the calcium pump in these acute in
vitro studies.
Discussion
The "uremic syndrome" reflects multiple organ toxicity by a
variety of substances retained by the failing kidney. The precise
identification of the toxins responsible for these symptoms re-
mains elusive [1]. Part of the difficulty is that toxicity may result
from the synergism between several accumulated solutes [1].
Alternatively, a central mechanism in cell biology may be com-
promised, and we have postulated that abnormalities in calcium
transport by the cell membrane may play a major role as the
biochemical basis of the uremic syndrome [5]. For instance,
maintenance of a low cytosolic calcium concentration, about i0—
mol/liter, is a critical function in cell biology [13]. Indeed, a high
calcium concentration is poorly tolerated and may lead to cell
death [4]. In this context, a plethora of reports have demonstrated
an increased cytosolic calcium concentration in a variety of cells in
renal failure, such as the RBC [6, 14], and platelets [15] in
humans, and brain synaptosomes [16], cardiac myocytes [17], T
cells [18], and pancreatic islets [19] in rats. One possible mecha-
nism that may result in a high cytosolic calcium concentration is
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Fig. 9. Presence of an inhibitor of the calcium pump was confirmed using
three different assay systems. In this case, P04-free AP Sephadex peaks were
tested for an effect on the calcium ATPase activity in isolated RBC
membranes. In spite of the smaller dose that was available, there was a
strong inhibitory effect of peaks AP5 and AP8, and clear effects of AP6,
AP1O and API I on calmodulin-activated (CaM) calcium ATPase activity.
These peaks had little effect on the calcium ATPase in its basal state, or
other ion ATPases (not shown).
Table 2. Comparison of inhibitory effect of selected subfractions using
a specific 45calcium assay in intact RBCs
% Inhibition in each bioassay
Peaks Sr2 RBC Membranes 45Ca2
A. Comparison of AP peaks from Step 2
APi 46 N/A 24
AP6 15 N/A 10
AP7 55 N/A 36
B. Comparison of AP peaks from Step 3
AP 6/Sif 14 50 31 17
AP 8/Sif 11 22 25 25
AP8/Sff14 19 11 22
number of AP peaks obtained at Steps 2 (analytical HPLC,
containing phosphate) and Step 3 (Sephadex removal of phos-
phate) also inhibit 45Ca2 transport. It should be noted that the
results are not strictly comparable because the methods and
dilutions differed. In addition, a few Sephadex subfractions (Ssf)
were available for confirmatory measurements. Thus, we found
that Ssfl4 from AP6 and SsflI and Ssfl4 from AP8, all inhibited
45Ca2 efflux and the calcium ATPase by more than 10%.
Step 4: Identification of specific substances found in active
subfractions
A summary of the compounds identified in active sub-fractions
by the different analytical methods is given in Table 3. Initially, we
characterized a number of substances in F2 by their retention
time, in comparison with the elution of known compounds. This
procedure demonstrated the possible presence of arginine, creat-
me, dimethylamine, glucose, guanidinosuccinic acid, spermine,
spermidine and urea in F2.
MS analysis of SF6 revealed arginine, propionic acid, lactic acid
and proline. Enzymatic analysis demonstrated the presence of
urea in AP2 and glucose in AP6. Peaks AP6, AP7, AP8 and AP9,
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Table 3. Identity of specific substances found in inhibitory subfractions
F2 SF6 AP2 AP6 AP7 AP8 AP9
RT/SPIKING MS Enzymatic analysis GC-MS
arginine arginine urea glucose talose glucitol a-D-galactopyranose
creatinine lactic acid altrose glucose f3-D-glucopyranose
dimethylamine proline mannose inositol o-D-mannopyranose
glucose propionic acid D-glucose L-altrose D-glucose
guanidinosuccinic 13-D-glucopyranosc mannose inositol
spermidine rs-D-glucitol 13-D-glucopyranose
spermine a-D-mannopyranose
urea talose
CE
acetic acid glycolic acid
actic acid lactic acid
acetic acid
lactic acid
NMR
3-OH-butyrate creatinine alanine
alanine glutamate glutamate
Betaine glutamine glutamine
dimethylglycine lactic acid lactic acid
glutamate mannitol mannitol
glutamine myo-inositol myo-inositol
guanidinoacetic acid polyols
lactic acid sugars
polyols
sugars
trimethylamine-N-oxide
valine
amino acids
glycine
lactic acid
myo-inositol
organic acids
polyols
sugars
Table 4. Individual compounds evaluated for possible inhibition of the calcium pump in RBC
Substance Concentration Substance Concentration
Alanine 4 ms Glutamine 17 mM
Arginine 96 and 960 jM Guanidinoacetic acid 3 /LM
Arsenic 75 mM 3-D-Hydroxybutyrate 1.5 mM
Arseno-betaine 75 and 750 zM Lactic acid 7 mvt
Betaine 75 jrrvi Lysine 2 mi
Choline 25 rM Mannitol 1 mM
Creatinine 80 and 800 rM, 1.3 mi Myoinositol 550 /LM
Cysteine 0.6 m Polyethylene glycol 1 mM
Cystine 0.08 mivi Proline 18.3 and 183 jrM
3-Deoxy-glucosone 1 ig/ml Propionic acid 1.7 and 17 zM
Dimethylglycine 10 rM Ac-SDKP (acetyl-ser-asp-lys-pro) 18 and 180 pmol/ml
Glucose 10 mivi Sorbitol 1 mM
Glutamate 100 jzM Trimethylamine-N-oxide
Urea
50 jzM
3.3 and 33 m'vi
the impairment of calcium efflux. Thus, Gafter et al suggested that
the Ca2-ATPase activity of the cell membrane was inhibited in
RBC, possibly due to the presence of a dialyzable humoral factor
in uremia [20]. Shortly thereafter, Lindner et a! reported a
circulating inhibitor of the RBC membrane calcium pump in
patients with chronic renal failure [5]. A similar inhibitor of the
Ca2-ATPase activity (the enzymatic counterpart of calcium
transport by the calcium pump) was confirmed by Zidek et al [6]
in humans, and by Massry and colleagues in brain synaptosomes
[16] and pancreatic islets [19] in the rat.
In our initial report we described a low molecular weight factor
that was dialyzable and heat stable, and that increased in concen-
tration in proportion to the loss of renal function [5]. In an effort
to identify this factor and determine its biochemical structure, in
the present studies we analyzed uremic plasma by high perfor-
mance liquid chromatography (HPLC). This method has been
previously used with success by our group to isolate the plasma
fractions responsible for the depressed phagocytic function [21]
and the changes in drug protein binding in uremia [22], and to
demonstrate the role of uric acid and the purine analogues on
calcitriol metabolism [23, 24].
For the evaluation of cellular Ca2 efflux, we used the mea-
surement of Sr2 efflux by atomic absorption spectrophotometsy
(AA) as the primary bioassay. This method was validated in our
early work, and nonspecific effects were not observed [5]. Using
preparative HPLC (Step 1) we found a single fraction (F2) that
1050 Lindner et a!: Calcium pump inhibitors in uremic plasma
contained most of the calcium pump inhibitory activity, and
displayed a linear dose-response (Figs. 4 and 5). This fraction was
characterized by the presence of small hydrophilic compounds,
such as creatinine, glucose, spermine and spermidine, urea and
electrolytes, including phosphate. Because electrolytes may inter-
fere with our bioassay by a "matrix" effect during AA, we
proceeded to desalt UF by ion-exchange chromatography (Step
1). Although part of the inhibition was lost during desalting, when
the materials were lyophilized and re-concentrated in a smaller
volume, calcium pump inhibition was demonstrated again with a
linear dose-dependent effect (Fig. 5). Therefore, the inhibitor was
not phosphate or a salt in the test media.
To narrow the isolation of the inhibitory factor, we subjected
the active desalted UF to additional chromatographic separation
into eight smaller subfractions (Step 1). This confirmed the
presence of an inhibitor in subfraction SF6. To further separate
these materials, we proceeded to analytical HPLC (Step 2), using
an aminopropyl column with polar NH2-groups and elution with a
decreasing gradient profile of phosphate buffer/acetonitrile, which
gave the best resolution. At this step, it became necessary to
exclude a potential artifact on the Sr2 bioassay, since a high
concentration of phosphate was re-introduced into the test sys-
tem, which may interfere with AA measurements. Therefore,
phosphate was removed from these subfractions by Sephadex G25
(Step 3). We found that fractions without phosphate continued to
inhibit cation transport in the bioassay, sometimes more strongly
than the same material containing this electrolyte.
At this stage of the study we felt that it was important to
confirm these effects using additional bioassays, including a more
direct measurement of calcium transport. The importance of
demonstrating a biological effect on more than one assay was
underlined by Woolfson, Poston and de Wardener [25], who
showed that digitalis-like immunoreactivity was not always indic-
ative of the presence of a true inhibitor of membrane sodium
transport in uremia. Actual measurement of sodium transport is
also necessary. Therefore, we demonstrated that the factor(s)
inhibited the reaction in three different complementary systems:
(1) Sr2 transport in intact RBC; (2) calcium ATPase activity in
isolated RBC membranes; and (3) active transport by the RBC
membrane calcium pump, assessed with 45Ca in intact cells.
Neither of the latter two methods is sensitive to phosphate
interference. Thus, we confirmed that several subfractions inhib-
ited the calcium pump in more than one bioassay, including actual
calcium transport with 45Ca. These comparisons were only qual-
itative, because dilutions and sensitivity of each method differ and
prevent exact quantitation of effects.
In our earlier work we found that uremic plasma contained a
small inhibitor of the calcium pump that was dialyzable and heat
stable [5]. In the present study, the HPLC approach was helpful to
reveal a number of compounds that are associated with the
inhibitory effect. These compounds are all hydrophilic, and in-
clude sugars, weak low molecular weight organic acids and bases,
and some amino acids. The active substance is probably smaller
than 2000 Daltons, the cut-off for the C18 RP HPLC-procedure.
Since the largest molecular weight found by the analytical meth-
ods MS, GC-MS, CE and NMR was for the sugars (180.2 Da), we
can hypothesize that the compound(s) of interest will be in that
molecular weight range. Detection at low UV absorption (195
nm) was made possible by the choice of the eluents, and twelve
AP peaks (APi to AP12) could be detected. It should be stressed
that the AP peaks showed no or little UV-absorbance (254 nm),
suggesting that the substance(s) of interest contains neither
aromatic structure or double bonds. This was confirmed with
NMR. These methods only identified one compound with an
aromatic structure, creatinine, and the guanidino compounds.
The substances identified in the inhibitory subfractions are
listed on Table 3. These include compounds known to interfere
with physiologic and biochemical functions. For instance, the
guanidines, one of the major retention products in uremia, have
increased content in the brain [26], and their plasma levels
correlate with decreased nerve conduction velocity in children
receiving dialysis [27]. They may also decrease natural killer cell
activity [28], and the production of calcitriol [29]. Lactate may
interfere with the central nervous system response to acid-base
regulation [30], and with immune cell function [31]. Glutamate is
believed to be the major excitatory transmitter in the mammalian
central nervous system. Its concentration in the brain must be
kept low to maintain normal brain function [32]. Myoinositol has
been associated with neurotoxicity in uremia [33], and is involved
in cell volume regulation [34]. The osmolyte betaine is involved in
homocysteine breakdown, which in turn has been related to
premature vascular disease [35]. Polyamines such as spermine and
spermidine interfere with cellular functions, and may inhibit
erythropoiesis [36]. Di- and trimethylamines are retained in
uremia, and their intracellular concentrations are higher than in
plasma [37]. Early studies showed that they inhibit fibroblast cell
function [38]. Finally, the inhibitory fractions contained a complex
mixture of sugars. Glucose has been reported to inhibit the RBC
calcium pump by non-enzymatic glycation [39], and it may be
increase cytosolic calcium in some cells in diabetes [40]. Sugars
may be linked to other compounds and result in advanced
glycosilation products (AGE), which are increased in dialysis
patients [41], and are known to cause many functional and
structural changes [42, 43]. However, we have no information
about glycosilation products in our in vitro studies.
Initially, most of our efforts were directed towards the chro-
matographic separation of small subfractions with biologic activ-
ity. Chemical analysis was then used to identify a number of
substances within these fractions. More recently, we have initiated
a systhematic evaluation of the individual compounds identified
so far, using the calcium ATPase assay as the primary screening
method. A list of the compounds evaluated so far are shown in
Table 4. In most cases we used concentrations approximately ten
times normal, as expected in uremic plasma. To our surprise, we
have not yet found one of these individual substances to have an
inhibitory effect on calcium transport. It should he noted that the
list tested, while large, is not exhaustive. It includes only some of
the substances present in these active fractions. In subsequent
work we will analyze other active peaks further by mass spectros-
copy and NMR. In addition, it cannot be excluded that a
combination of compounds may be needed for a synergistic
inhibitory effect. Thus, we have tested one compound, As-betaine,
because arsenic has been shown to accumulate in uremic plasma
[44], and the osmolyte betaine has been identified in our active
fractions. Neither of these compounds or their combination have
shown inhibitory effects. Other possible synergistic combinations
must be tested. Similarly, we have only looked at 3-deoxyglu-
cosorie, an acid substrate for the formation of AGES. Other
reports of calcium ATPase inhibition by glucose were obtained at
high pH and long incubation periods [39], and they cannot be
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compared with our studies. Other precursors should be tested,
and a more prolonged incubation period may be needed to
facilitate glycosilation in vitro. Finally, we have looked at one
endogenous biogenic peptide, Ac-SDKP (acetyl-ser-asp-lys-pro),
FW 487.5, recently described by Azizi et al [45], which accumu-
lates in uremic patients. This is a natural circulating inhibitor of
hematopoiesis, that regulates stem cell entry into S-phase. We
found no effect of this peptide on the calcium ATPase in RBC
membranes.
Our findings are in agreement with the attractive hypothesis
advanced by Massry and Fadda that "chronic renal failure is a
state of cellular calcium toxicity" [21. These authors have pro-
posed that PTH may increase cellular calcium content and, in
turn, inhibit the membrane calcium ATPase [11], [17]. In the
present studies, several lines of evidence suggest that PTH is not
responsible for our findings. First, this large polypeptide is
unlikely to be present in our fractions of uremic ultrafiltrates,
containing mostly hydrophilic compounds, smaller that 2,000
molecular weight. Second, acute additions of PTH (1-34 amino
terminal) or intact human PTH to the RBC bioassays were not
associated with an inhibition of cation transport. Other studies,
however, have required chronic administration of PTH for at least
three weeks in animals, to demonstrate an effect on the calcium
ATPase [11, 17]. Finally, in our previous study we found no
correlation between immunoreactive PTH levels in uremia and
the presence of an inhibitor of the calcium pump [5].
The importance of the present findings resides in the fact that
the membrane calcium transporter is ubiquitous in the body, and
its inhibition by a plasma factor in uremia may lead to increased
cytosolic calcium levels in a variety of cells. Thus, it may contrib-
ute to a number of serious complications, such as hypertension,
anemia, or nerve cell dysfunction, typical of the uremic syndrome.
Furthermore, precise identification of these factors may represent
the first finding of a true endogenous inhibitor of the calcium
pump, which has never been identified in the past [13]. HPLC
separation of the responsible substances has narrowed down the
search for these factors, detecting a substantial number of com-
pounds to be evaluated singly and in combination in future
studies. In the meantime, this up-to-date description of our
experience with chromatographic separation of uremic plasma
may be of help to others, and point the way for further progress in
this important field.
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